We can't find the internet
Attempting to reconnect
12667.1;4 PFLS-LS
HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic
Zusammenfassung
HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic
Weitere Texte
Abstract
A new and highly innovative treatment will be realized by a novel and patentable orally available small molecule combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic bacterial strains. The consortium integrates medicinal chemistry (Dr. Riedl, ZHAW), biological assays and screening (BioVersys AG) with high-end characterization of binding interactions (Prof. Dr. Gygax, FHNW). HIT compounds identified during two SATW projects will be developed into a clinical candidate utilizing all the experiences in the consortium.
Beteiligte
Rainer Riedl
Kontaktperson
rainer.riedl@zhaw.ch
ZHAW Rainer Riedl Einsiedlerstrasse 31 8820 Wädenswil ZH CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2011-10-31
- Enddatum
- 2014-03-11
- Bewilligte Gesamtkosten
- CHF 557507.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Nicht aufteilbare / nicht zuteilbare Forschung
Forschungsdisziplinen
- P004 Biochemistry, Metabolism 100.0%